IMMP

Immutep

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 0

Sell signal 1

Three Black Crows

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About IMMP

Immutep Limited

A biotech company that develops novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease

Industry

Biological Technology

Established Date

05/21/1987

Listing Date

04/16/2012

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

06-30

Website

www.immutep.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Level 32, Australia Square, 264 George Street, Sydney 2000, New South Wales, Australia

Business

Biotechnology and Medical Research

Introduction

Immutep Limited was incorporated in Australia on 21 May 1987. The company is a late-stage biotechnology company developing novel LAG-3-related immunotherapies for the treatment of cancer and autoimmune diseases. They are pioneers in understanding and advancing therapeutic approaches associated with lymphocyte activation gene -3 (LAG-3). Their diverse product portfolio leverages the unique ability of LAG-3 to regulate the body's immune response. Immutep is committed to leveraging its expertise to provide innovative treatment options to patients in need.

Company Financials

EPS

IMMP has released its 2022 Q2 earnings. EPS was reported at -0.02, versus the expected 0.00, missing expectations. The chart below visualizes how IMMP has performed over recent quarters, highlighting trends in earnings surprises.